Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2026-05-14 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物2025年年度股东会会议资料
AGM Information Classification · 95% confidence The document is titled “2025年年度股东会会议资料” and contains detailed meeting materials for the 2025 Annual General Meeting (AGM), including meeting notices, agenda, procedural rules, and explanatory notes for eight AGM proposals. It does not constitute the full annual report itself, but rather the presentation and materials for the shareholder meeting. Therefore, it fits the AGM Information category.
2026-05-14 Chinese
前沿生物关于续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's decision to renew the appointment of an accounting firm (audit firm) for the upcoming fiscal year 2026. It details the qualifications, background, and integrity of the audit firm and its personnel, the audit fees, and the approval process by the board and audit committee. It does not contain any actual financial statements or audit results but is a formal notice about the appointment of the auditor for the next fiscal year. This fits the category of a Regulatory Filing (RNS) because it is a regulatory announcement about auditor appointment rather than the audit report itself or the annual report.
2026-04-24 Chinese
前沿生物2025年度独立董事述职报告-王素梅
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 from a company listed on the Shanghai Stock Exchange STAR Market. It details the independent director's duties, attendance at board and shareholder meetings, committee work, communication with auditors, oversight of financial reports, and other governance-related activities during the year. The document does not contain financial statements or substantive financial data itself but is a narrative report on the independent director's work and oversight. It is not an annual report (10-K), audit report (AR), or management discussion and analysis (MDA). It is also not a proxy statement or voting results announcement. The document is a formal report by an independent director on their annual duties and observations, which fits best under Board/Management Information (MANG) as it relates to board-level governance and director activities. The document length is 4125 characters, which is relatively short and focused on director duties rather than full financial disclosures or audit results. Therefore, the classification is MANG with high confidence.
2026-04-24 Chinese
前沿生物2026年度“提质增效重回报”专项行动方案
Management Reports Classification · 95% confidence The document is titled as a "2026年度‘提质增效重回报’专项行动方案" which translates to a special action plan for quality improvement and efficiency enhancement for the year 2026. It contains detailed strategic plans, operational updates, governance improvements, R&D progress, investor relations activities, and risk disclosures. The content is forward-looking and strategic rather than a financial report or earnings announcement. It is a comprehensive management-level plan and report on company initiatives and governance, not a financial statement or audit report. There is no indication that this is an announcement of a report publication or a regulatory filing. The document is lengthy (over 6000 characters) and substantive, containing detailed management and governance information. Therefore, the best fitting category is "Management Reports (MDA)", which covers management's detailed explanation of business trends, strategies, and outlook.
2026-04-24 Chinese
前沿生物2025年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2025年度募集资金存放、管理与实际使用情况的专项报告" which translates to "2025 Annual Special Report on the Deposit, Management and Actual Use of Raised Funds." It details the company's fundraising activities, including amounts raised in 2020 and 2022, the management of these funds, their actual usage during the 2025 fiscal year, and compliance with regulatory requirements. The document includes detailed tables on fundraising, usage, cash management, and changes in investment projects. It also contains audit opinions from accounting firms and sponsors confirming compliance and proper use of funds. The document is lengthy (15,000 characters) and contains substantive financial data and analysis related to fundraising and capital usage. This matches the description of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising, financing activities, or capital structure changes. It is not an announcement of a report, nor a full annual report or interim report. It is a detailed report on fundraising and capital usage, fitting CAP best.
2026-04-24 Chinese
前沿生物关于变更2025年年度报告和2026年第一季度报告披露时间的公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (400 characters) about the change in disclosure dates for the 2025 Annual Report and 2026 First Quarter Report. It states the original and new disclosure dates and mentions the company's board and regulatory approval. There is no actual financial data or report content included, only a notice about timing changes. According to the 'Menu vs Meal' rule, this is an announcement about report publication timing, not the report itself. Therefore, the correct classification is Report Publication Announcement (RPA).
2026-04-21 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.